Frontier Wealth Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Frontier Wealth Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-24,300	Closed	-$250K	–	423
2016 Q4	$250K	Sell	24,300 -2,500	-9%	-$22.8K	0.04%	310
2016 Q3	$271K	Sell	26,800 -890	-3%	-$9.72K	0.04%	295
2016 Q2	$311K	Sell	27,690 -600	-2%	-$7.64K	0.05%	271
2016 Q1	$386K	Sell	28,290 -1,380	-5%	-$19.9K	0.03%	225
2015 Q4	$563K	Sell	29,670 -600	-2%	-$13K	0.09%	184
2015 Q3	$568K	Buy	30,270 +8,940	+42%	+$152K	0.09%	191
2015 Q2	$318K	Buy	+21,330	New	+$325K	0.05%	248

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Frontier Wealth Management's CNCE Position: Q1 2017 in Review

Frontier Wealth Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2017, closing a stake of 24,300 shares — an estimated $250K sold.

Frontier Wealth Management first reported a position in CNCE in Q2 2015 and held it in 7 quarters. The position peaked at $568K in Q3 2015. 85 funds tracked by Wall St. Rank hold CNCE as of Q1 2017.

Frontier Wealth Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Frontier Wealth Management sold 24,300 Concert Pharmaceuticals, Inc. shares in Q1 2017, an estimated $250K.
Frontier Wealth Management first reported a position in Concert Pharmaceuticals, Inc. in Q2 2015 and held it in 7 quarters.
Frontier Wealth Management's Concert Pharmaceuticals, Inc. position peaked at $568K in Q3 2015.
85 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2017.

Based on Frontier Wealth Management's 13F filing for Q1 2017, filed 12 May 2017.